ArticleActa pharmaceutica Sinica. B2025

CMD-OPT model enables the discovery of a potent and selective RIPK2 inhibitor as preclinical candidate for the treatment of acute liver injury.

Yong Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.